Extremely Drug-Resistant
            <i>Citrobacter freundii</i>
            Isolate Producing NDM-1 and Other Carbapenemases Identified in a Patient Returning from India

Poirel, Laurent; Ros, A.; Carricajo, Anne; Berthelot, Philippe; Pozzetto, Bruno; Bernabeu, Sandrine; Nordmann, Patrice

doi:10.1128/aac.01305-10

Cited by 124 publications

(82 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these seven episodes, there were six index cases who reported travel within the previous year to India and one to Iraq [23][24][25]. Five were hospitalised abroad before their transfer to a French hospital.…”

Section: Episodes Of Particular Importancementioning

confidence: 99%

Emergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011

Vaux

Carbonne²,

et al. 2011

Eurosurveillance

View full text Add to dashboard Cite

Emergence of carbapenemase-producing Enterobacteriaceae (CPE) is currently a major public health concern worldwide. This study showed that 53 episodes of CPE infection or colonisation have been notified by French healthcare facilities since 2004. A sharp increase in the number of notifications was observed in the last three years. Oxacillinase (OXA)-48 and Klebsiella pneumoniae carbapenemase (KPC) beta-lactamases were the most frequent enzymes reported in these episodes. The index cases in most episodes were patients with a history of hospitalisation abroad within the previous year. Around a third of the episodes (n=18) led to secondary transmission in hospitals but most of them were controlled due to reinforced measures. Reinforcement of screening and control measures at national level when there is cross-border transfer of patients, along with overall reinforcement of infection control and antimicrobial stewardship worldwide, is urgently needed to contain the spread of CPE.

show abstract

Section: Episodes Of Particular Importancementioning

confidence: 99%

Emergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011

Vaux

Carbonne²,

et al. 2011

Eurosurveillance

View full text Add to dashboard Cite

show abstract

“…Several international surveillance programs have reported the frequent isolation of multi-resistant strains resistant to beta-lactams, quinolones, and aminoglycosides among C. freundii and C. koseri species (Jones et al 2000;Perilli et al 2005;Kanamori et al 2011). Particularly for C. freundii, strains highly resistant to all beta-lactams (e.g., MIC >256 μg/ml for ceftriaxone and cefotaxime), as well as to aminoglycosides (e.g., MIC >256 μg/ml for gentamycin and amikacin), fluoroquinolones (e.g., MIC >32 μg/ml for ciproflioxacin), sulfonamides, tetracycline, tigecycline, and nitrofurantoin, have been detected (Zhang et al 2008;Institute CaLS 2010;Poirel et al 2011). New antibiotics in the development pipeline are mostly oriented against Gram-positive species.…”

Section: Introductionmentioning

confidence: 99%

Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates

Oliveira

Pinto

Oliveira

et al. 2016

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Citrobacter spp., although frequently ignored, is emerging as an important nosocomial bacterium able to cause various superficial and systemic life-threatening infections. Considered to be hard-to-treat bacterium due to its pattern of high antibiotic resistance, it is important to develop effective measures for early and efficient therapy. In this study, the first myovirus (vB_CfrM_CfP1) lytic for Citrobacter freundii was microbiologically and genomically characterized. Its morphology, activity spectrum, burst size, and biophysical stability spectrum were determined. CfP1 specifically infects C. freundii, has broad host range (>85 %; 21 strains tested), a burst size of 45 PFU/cell, and is very stable under different temperatures (−20 to 50°C) and pH (3 to 11) values. CfP1 demonstrated to be highly virulent against multidrug-resistant clinical isolates up to 12 antibiotics, including penicillins, cephalosporins, carbapenems, and fluroquinoles. Genomically, CfP1 has a dsDNA molecule with 180,219 bp with average GC content of 43.1 % and codes for 273 CDSs. The genome architecture is organized into function-specific gene clusters typical for tailed phages, sharing 46 to 94 % nucleotide identity to other Citrobacter phages. The lysin gene encoding a predicted D-Ala-D-Ala carboxypeptidase was also cloned and expressed in Escherichia coli and its activity evaluated in terms of pH, ionic strength, and temperature. The lysine optimum activity was reached at 20 mM HEPES, pH 7 at 37°C, and was able to significantly reduce all C. freundii (>2 logs) as well as Citrobacter koseri (>4 logs) strains tested. Interestingly, the antimicrobial activity of this enzyme was performed without the need of pretreatment with outer membrane-destabilizing agents. These results indicate that CfP1 lysin is a good candidate to control problematic Citrobacter infections, for which current antibiotics are no longer effective.

show abstract

“…The bla OXA-181 gene has been associated with other carbapenemase genes, including the NDM-1 (Castanheira et al, 2011), NDM-5 (Cho et al, 2015), and VIM-4 genes (Poirel et al, 2011). In Africa, the bla OXA-181 gene has only been reported in Angola (Kieffer et al, 2016) and South Africa (Brink et al, 2013).…”

mentioning

confidence: 99%